# A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects

> **NCT05857215** · PHASE1 · COMPLETED · sponsor: **Galmed Pharmaceuticals Ltd** · enrollment: 55 (actual)

## Conditions studied

- Inflammatory Disease

## Interventions

- **DRUG:** amilo-5MER

## Key facts

- **NCT ID:** NCT05857215
- **Lead sponsor:** Galmed Pharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-03-05
- **Primary completion:** 2021-07-01
- **Final completion:** 2021-07-01
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2023-05-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05857215

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05857215, "A First-in-Human Study of Single and Multiple Doses of Amilo-5MER in Healthy Subjects". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05857215. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*